GSDMD and liver dysplastic nodule: Diabetic nephropathy (DN) occurs in about 40% of diabetes patients and is the primary cause of microvascular complications and end-stage renal disease.470 Numerous reviews have concluded that pyroptosis participates in the onset and progression of DN,471–474 and to a significant degree, inhibiting pyroptosis is tantamount to mitigating the harm caused by DN, and GSDMD inhibition might be an essential target.